摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-methylquinazoline-2-amine | 1169789-21-2

中文名称
——
中文别名
——
英文名称
8-methylquinazoline-2-amine
英文别名
8-Methylquinazolin-2-amine
8-methylquinazoline-2-amine化学式
CAS
1169789-21-2
化学式
C9H9N3
mdl
——
分子量
159.191
InChiKey
UZDOMJBWUXDEBS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    51.8
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PENTADIENAMIDE DERIVATIVE
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP2050734A1
    公开(公告)日:2009-04-22
    The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R3 represents a hydrogen atom or is combined together with R4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R5, R6, and R7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.
    本发明提供了一种由式(I)表示的戊二烯酰胺衍生物:(其中R1代表取代或未取代的芳基或取代或未取代的芳香族杂环基;R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物;R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基;R4代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物,或与R3及其相邻的氮原子结合形成取代或未取代的杂环基;R5、R6和R7可以相同也可以不同,每个代表氢原子或甲基)或其药学上可接受的盐等。
  • 2-AMINOQUINAZOLINE DERIVATIVE
    申请人:Sawa Masaaki
    公开号:US20100311965A1
    公开(公告)日:2010-12-09
    An object of the present invention is to provide compounds which are useful as protein kinase inhibitors. Disclosed is a 2-aminoquinazoline derivative represented by the following formula (I): wherein R 1 represents a lower alkyl group which may be substituted with a halogen atom, or a halogen atom; R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted acylamino group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, or a substituted or unsubstituted lower alkylureido group; and X, Y and Z each independently represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a halogen atom, a hydroxyl group, a carboxyl group, a lower alkoxycarbonyl group, a cyano group, a carbamoyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted lower alkoxycarbonylamino group, a substituted or unsubstituted lower alkylaminocarbonyl group, a lower alkylsulfonylamino group, a substituted or unsubstituted lower alkylureido group, or a substituted or unsubstituted acylamino group, or X and Y may be combined to form a 5- to 6-membered ring forming a bicyclic fused ring, wherein the 5- to 6-membered ring may optionally have a substituent, provided that when X and Y are not combined to form a fused ring, R 2 represents a hydrogen atom and, when X and Y are combined to form a fused ring, a saturated or unsaturated, bicyclic alicyclic or heterocyclic fused ring can be formed.
    本发明的目的是提供可用作蛋白激酶抑制剂的化合物。公开的是一种由以下式(I)表示的2-氨基喹唑啉衍生物:其中R1表示可以被卤素原子取代的低级烷基基团或卤素原子;R2表示氢原子、取代或未取代的低级烷基基团、卤素原子、羟基、取代或未取代的低级烷氧基团、取代或未取代的氨基、取代或未取代的酰胺基、羧基、低级烷氧羰基基团、氨基甲酰基基团、氰基、取代或未取代的低级烷氧羰胺基团、取代或未取代的低级烷基氨基甲酰基团、低级烷基磺酰氨基基团、取代或未取代的低级烷基脲基基团或取代或未取代的酰胺基;X、Y和Z各自独立地表示氢原子、取代或未取代的低级烷基基团、卤素原子、羟基、羧基、低级烷氧羰基基团、氰基、氨基甲酰基基团、取代或未取代的低级烷氧基团、取代或未取代的低级烷氧羰胺基团、取代或未取代的低级烷基氨基甲酰基团、低级烷基磺酰氨基基团、取代或未取代的低级烷基脲基基团或取代或未取代的酰胺基,或X和Y可以结合形成一个5-到6-成员环形成一个双环融合环,其中5-到6-成员环可以选择地具有取代基,但是当X和Y没有结合形成融合环时,R2表示氢原子;当X和Y结合形成融合环时,可以形成饱和或不饱和、双环融合脂环或杂环融合环。
  • PENTADIENAMIDE DERIVATIVES
    申请人:NAKASATO Yoshisuke
    公开号:US20090203667A1
    公开(公告)日:2009-08-13
    The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R 3 represents a hydrogen atom or is combined together with R 4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R 4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R 3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R 5 , R 6 , and R 7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.
    本发明提供了一种由以下公式(I)表示的五二烯酰胺衍生物:(其中,R1代表取代或未取代的芳基或取代或未取代的芳香杂环基;R2代表取代或未取代的芳基,取代或未取代的芳香杂环基,取代或未取代的杂环螺环基或类似物;R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基;R4代表取代或未取代的芳基,取代或未取代的芳香杂环基,取代或未取代的杂环螺环基或类似物,或与R3及其相邻的氮原子结合形成取代或未取代的杂环基;R5、R6和R7可以相同也可以不同,每个代表氢原子或甲基)或其药学上可接受的盐等。
  • [EN] 2-AMINOQUINAZOLINE DERIVATIVE<br/>[FR] DÉRIVÉ DE 2-AMINOQUINAZOLINE
    申请人:CARNA BIOSCIENCES INC
    公开号:WO2009084695A1
    公开(公告)日:2009-07-09
    本発明は下記式(I)で示されるプロテインキナーゼ阻害剤として有用な化合物を提供する。(式中、R1 は、ハロゲン原子で置換されていてもよい低級アルキル基、ハロゲン原子等を表し、R2 は、水素原子、置換もしくは非置換の低級アルキル基等を表し、X、Y及びZ は、夫々独立して、水素原子、置換もしくは非置換の低級アルキル基等を表すか、あるいはXとY とが一緒になって、置換基を有することもある5ないし6員環を形成することによって、2環性縮合環を形成してもよい。)
  • EP2226315
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多